Blackstone Life Sciences and Anthos Therapeutics, Inc. (“Anthos” or the “company”), a transformative, clinical-stage biopharmaceutical company developing innovative therapies for the treatment of cardiometabolic diseases, announced today that the company has entered into an agreement with Novartis to acquire Anthos for up to $3.1 billion. Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel factor XI inhibitor that originated at Novartis, being developed to prevent stroke and systemic embolism in patients with atrial fibrillation as well as to prevent the recurrence of blood clots in patients with cancer.
Read the full article: Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to Be Acquired by Novartis for up to $3.1B //
Source: https://www.businesswire.com/news/home/20250210114240/en/Blackstone-Life-Sciences-and-Anthos-Therapeutics-Announce-Agreement-for-Anthos-to-be-Acquired-by-Novartis-for-up-to-3.1-Billion